CONSONANCE's digitally enhanced MS endpoint cut required sample size 24.9%. Here's what that number costs in protocol ...
A Nature Biotechnology phase 2a trial ran six proteomic aging clocks simultaneously, here's what that means for biomarker ...
JST-018 orthopoxvirus antibody enters phase 1 trial under $123.9M defense contract with Just-Evotec Biologics for warfighter ...
Advarra releases IRB reportable events checklist to help research teams distinguish critical safety signals from minor ...
Novartis triggers $50M milestone payment as MRT-6160 enters Phase 2 for Sjögren's disease, advancing VAV1 degrader ...
Mosliciguat advances to Phase 3 PHrontier Trial after PHocus Study shows 20% pulmonary vascular resistance reduction in ...
Nektar will release 24-week off-treatment data for rezpegaldesleukin in alopecia areata, testing durability after dosing ends in the Phase 2b REZOLVE-AA study.
BridgeBio shifts BBO-8520 focus to KRAS combinations in second-line NSCLC, building on a 63% response rate from monotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results